Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). INBRX-106 clinical updates in first-line head and neck squamous cell carcinoma, a material development-stage program.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- INBRX-106 clinical updates in first-line head and neck squamous cell carcinoma, a material development-stage program
- Disclosure delivered through a September 8, 2026 press release under Regulation FD
- Investors should review the accompanying exhibit for trial data, safety findings, and development implications
Item 8.01 · Other Events
- INBRX-106 plus pembrolizumab delivered 48.3% cORR versus 26.5% for pembrolizumab alone
- Combination arm showed 13.8% complete responses versus none for control
- Median PFS reached 9.6 months versus 4.9 months; six-month PFS 72.4% versus 42.8%
- HPV+ subgroup showed 80.0% cORR and 90.0% six-month PFS with combination therapy
- Planned expansion adds approximately 50 HPV+ OPSCC patients, supporting potential accelerated regulatory pathway and Phase 3 initiation
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 HNSCC data: cORR 48.3% with INBRX-106 plus pembrolizumab versus 26.5% monotherapy
- Median PFS 9.6 months versus 4.9 months, with six-month PFS 72.4% versus 42.8%
- HPV+ subgroup showed 80.0% cORR, 30.0% complete response rate, and 90.0% six-month PFS
- Approximately 50 additional HPV+ OPSCC patients planned, supporting potential accelerated-approval pathway
- Positive data expand potential into earlier-stage OPSCC, NSCLC, other immunogenic tumors, and cancer-vaccine combinations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.